The U.S. Food & Drug Administration (FDA) has tentatively approved Alembic Pharmaceuticals‘ generic formulation of injectable selexipag as a…
Articles by Steve Bryson, PhD
A SIRT3 protein deficiency in skeletal muscles, which are attached to bones, was related to pulmonary hypertension associated with…
Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with…
Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO)…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S.
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with…
Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature…
An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system…
Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of…
The activation of clinical sites for a global Phase 3 study to evaluate Gossamer Bio’s inhaled seralutinib (GB002), an…
Four proteins related to a pro-inflammatory signaling molecule called TNF-alpha may serve as biomarkers to predict mortality in adults with…
Researchers have identified three proteins — NID1, C1QTNF1, and CRTAC1 — in the bloodstream of people with pulmonary hypertension…